DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Striant (Testosterone Buccal System) - Drug Interactions, Contraindications, Overdosage, etc




Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.


In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.


Concurrent administration of testosterone with ACTH or corticosteroids may enhance edema formation and should be administered cautiously, particularly in patients with cardiac or hepatic disease.


There is one report of acute overdosage with testosterone enanthate injection: testosterone levels of up to 11,400 ng/dL were implicated in a cerebrovascular accident.

Oral ingestion of Striant® is not expected to result in clinically significant serum testosterone concentrations due to extensive first-pass (hepatic) metabolism.


Androgens are contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate.

Striant® is not indicated for use in women, and must not be used in women. Testosterone supplements may cause fetal harm.

Striant® should not be used in patients with known hypersensitivity to any of its ingredients, including testosterone USP that is chemically synthesized from soy.


Striant® contains testosterone, a Schedule III controlled substance as defined by the Anabolic Steroids Control Act.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017